The stock of Alx Oncology Holdings Inc (NASDAQ: ALXO) has decreased by -5.09 when compared to last closing price of 2.75.Despite this, the company has seen a loss of -45.63% in its stock price over the last five trading days. globenewswire.com reported 2024-08-06 that – Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development – – Jaume Pons, Ph.D., and Sophia Randolph, M.D.
Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?
Additionally, the 36-month beta value for ALXO is 1.25. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALXO is 29.79M and currently, short sellers hold a 26.02% ratio of that float. The average trading volume of ALXO on August 07, 2024 was 1.25M shares.
ALXO’s Market Performance
ALXO stock saw a decrease of -45.63% in the past week, with a monthly decline of -58.96% and a quarterly a decrease of -85.14%. The volatility ratio for the week is 21.03%, and the volatility levels for the last 30 days are 13.74% for Alx Oncology Holdings Inc (ALXO). The simple moving average for the past 20 days is -55.40% for ALXO’s stock, with a -77.07% simple moving average for the past 200 days.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Stifel repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Stifel is $14 based on the research report published on March 08, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $18, previously predicting the price at $8. The rating they have provided for ALXO stocks is “Buy” according to the report published on December 08th, 2023.
Jefferies gave a rating of “Hold” to ALXO, setting the target price at $25 in the report published on December 22nd of the previous year.
ALXO Trading at -63.27% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.36% of loss for the given period.
Volatility was left at 13.74%, however, over the last 30 days, the volatility rate increased by 21.03%, as shares sank -61.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.18% lower at present.
During the last 5 trading sessions, ALXO fell by -45.63%, which changed the moving average for the period of 200-days by -62.98% in comparison to the 20-day moving average, which settled at $5.64. In addition, Alx Oncology Holdings Inc saw -82.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pons Jaume, who sale 20,000 shares at the price of $7.90 back on Jul 11 ’24. After this action, Pons Jaume now owns 593,447 shares of Alx Oncology Holdings Inc, valued at $158,076 using the latest closing price.
Pinto Shelly, the SVP, FINANCE AND CAO of Alx Oncology Holdings Inc, sale 1,823 shares at $5.50 during a trade that took place back on Jul 05 ’24, which means that Pinto Shelly is holding 92,113 shares at $10,025 based on the most recent closing price.
Stock Fundamentals for ALXO
Current profitability levels for the company are sitting at:
- -70.9 for the present operating margin
- 0.54 for the gross margin
The net margin for Alx Oncology Holdings Inc stands at -67.02. The total capital return value is set at -0.97. Equity return is now at value -82.16, with -67.73 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -12.23. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -213.65.
Currently, EBITDA for the company is -169.44 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 56.59. The receivables turnover for the company is 2.25for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.21.
Conclusion
In conclusion, Alx Oncology Holdings Inc (ALXO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
